Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non –small cell lung cancer patients with asymptomatic brain metastases
Conclusion: Ramucirumab in combination with erlotinib or osimertinib showed safety forEGFR-mutated NSCLC with brain metastases.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Brain | Brain Cancers | Cancer | Cancer & Oncology | Drugs & Pharmacology | Hemorrhagic Stroke | Hypertension | Investigational New Drugs | Lung Cancer | Neurology | Non-Small Cell Lung Cancer | Oral Cancer | Study | Tarceva | Toxicology